Human interleukin-2

Iovance Biotherapeutics reports $58.6M in 3Q24 product revenue for Amtagvi™ (Lifileucel), reaffirming $160-$165M FY24 and $450-$475M FY25 guidance. European regulatory authorities validate and accept marketing authorization applications for potential approval starting in 1H2025 for the UK and 2H2025 for EU and Canada. Enrollment accelerates in IOV-LUN-202 Phase 2 trial in post-anti-PD-1 NSCLC.

Weekend warrior activity linked to lower dementia risk; physical activity post-dementia diagnosis reduces mortality; deferiprone worsens early Alzheimer's; bepranemab shows mixed results; LX1001 improves APOE2 and tau biomarkers; low-dose interleukin-2 safe in Alzheimer's; out-of-pocket costs for neuro drugs rise; autism diagnoses increase; Alzheimer's GWAS data criticized; NHLPA forms CTE advisory committee; debate on reporting medically impaired drivers.

The study involved ethical approval, leukapheresis for NK cell production, and adherence to GMP regulations. NK cells were manufactured using CliniMACS Prodigy, with quality control including sterility testing, cell count, and viability analysis. Cell lines and primary NK cells were isolated and cultured for cytotoxicity and degranulation assays.

A trial tested Guanxinning tablets, a combination of Salvia miltiorrhiza and Ligusticum chuanxiong, to reduce residual inflammation risk (RIR) in stable coronary artery disease (SCAD) patients on standard atherosclerotic cardiovascular disease (ASCVD) treatment. Results showed Guanxinning effectively lowered inflammation-related indicators (IL-2, IL-6, TNF-α, hs-CRP), improved blood lipid profiles (Tch, LDL-C), and endothelial function (VEGF, NO, PPAR-γ), without increasing safety risks like liver or kidney dysfunction, anemia, or bleeding.

Coya Therapeutics to discuss Phase 2 trial results of LD IL-2 in Alzheimer’s patients on Oct 29, 2024, at 8am ET, with a webcast available. The trial, funded by Alzheimer’s Association, Gates Foundation, and National Institute on Aging, was led by Dr. Alireza Faridar and Dr. Stanley Appel.

AU-007 shows unique Treg reduction and longer PFS, with increased tumor-killing Teffs, differentiating it from other IL-2 therapeutics. Phase 2 efficacy and safety data to be presented.

Rice University and Baylor College of Medicine researchers developed a treatment combining cytokine 'drug factory' implants and checkpoint inhibitor drugs, which eradicated advanced-stage mesothelioma tumors in mice within days. The treatment involves tiny IL-2-producing beads implanted near tumors, showing promising results in preclinical trials and paving the way for clinical trials in ovarian and mesothelioma patients.

Phase 2 open-label study in Panama and Philippines (2017-2020) evaluated TAK-003 vaccine in healthy children (4-16 years in Panama, 4-8 years in Philippines). Two-dose schedule on Days 1 and 90, with blood samples for serostatus, T cell, and NAb assessments. Primary objective: IFN-γ ELISPOT T cell response 1 month post-second dose. Secondary: T cell responses, NAb titers, seropositivity, safety up to 3 years. Post-hoc: T cell and NAb responses in virologically-confirmed dengue cases. No formal statistical hypotheses; data presented descriptively.

Transgene's Phase II study of TG4001 in combination with avelumab did not meet the primary objective of improving progression-free survival in HPV16-positive cervical and anogenital tumors. However, a positive efficacy trend was observed in cervical cancer patients, prompting further analysis. Transgene will complete a full data analysis before deciding the future of TG4001.

Aulos Bioscience presents promising Phase 2 data for AU-007, an IL-2 therapeutic, in advanced solid tumors at SITC 39th Annual Meeting, showcasing safety and efficacy.